论文部分内容阅读
Objective:The aim of this study was to investigate the early outcome of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancer.Methods:Forty-two cases with cervical cancer (FIGO IIb to IVa) were divided randomly into two groups,radiotherapy alone (RT group:21 cases) and radiation combines chemotherapy (nedaplatin and megestrol) (RT+ C group:21 cases).There was no difference of radiotherapy between the two groups,the RT+ C group accepted nedaplatin injection during the radiation weekly,according to 30 mg/m 2,these regimen were given for 4-5 weeks.This group was received an oral medicine megestrol 160 mg every day during the treatment.Results:The RT+ C group:the complete remission rate was 80.9% (17/21),the partial remission rate was 19.1% (4/21),the effective rate was 100%.The RT group:the complete remission rate was 38.1% (8/21) and partial remission rate was 32.9% (9/21),the effective rate was 81.0%.The total effective rate and complete remission rate of RT+ C group were higher than RT group.There was significant difference between the two groups.The 1-year survival rates respectively were 100% (21/21) in RT+ C group,80.9% (17/21) in RT group.There was statistically significant difference between the two groups (χ2=4.42>3.84,P<0.05).Conclusion:The nedaplatin and megestrol combine chemoradiotherapy can improve the early outcome of the advanced cervical cancer,and the adverse effects was raised,but that can be endured.
Objective: The aim of this study was to investigate the early outcome of the nedaplatin and megestrol combine chemoradiotherapy to the advanced cervical cancer. Methods: Forty-two cases with cervical cancer (FIGO IIb to IVa) were divided randomly into two groups, radiotherapy alone (RT group: 21 cases) and radiation labeled chemotherapy (nedaplatin and megestrol) (RT + C group: 21 cases). There was no difference of radiotherapy between the two groups, the RT + C group accepted nedaplatin injection during the radiation weekly, according to The regimen was given for 4-5 weeks. This group was received an oral medicine megestrol 160 mg every day during the treatment. Results: The RT + C group: the complete remission rate was 80.9% (17/21 The partial remission rate was 38.1% (8/21) and partial remission rate was 32.9% (9/21). The partial remission rate was 19.1% (4/21) , the effective rate was 81.0%. The total effective rate and complete remission rate o f RT + C group were higher than RT group. There was significant difference between the two groups. The 1-year survival rates were changed 100% (21/21) in RT + C group, 80.9% (17/21) in RT group. Conclusions: The nedaplatin and megestrol combine chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and the adverse effects was raised, but that can be endured.